Home
|
Inbox
|
Search
|
View Abstract
Prognostic Value of Systemic Immune Inflammation Index in Advanced Non Small Cell Lung Cancer
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A7331 - Prognostic Value of Systemic Immune Inflammation Index in Advanced Non Small Cell Lung Cancer
Author Block: L. Dan, Y. Xia, Y. He, L. Weimin; West China Hospital, Sichuan University, Chengdu, China.
Background: Previous studies reported that systemic immune-inflammation index (SII) was associated with clinical outcome of several tumors. However, data related to lung cancer was rare. This study aims to clarify the clinical significance of SII in patients with advanced non-small cell lung cancer (NSCLC).
Methods: A total of 523 patients with staged III/IV NSCLC were enrolled in this retrospective study. SII was calculated with the formula SII = (platelet ×neutrophil)/ lymphocyte. The association among SII and clinical characteristics and overall survival (OS) of NSCLC was assessed. Propensity score matching (PSM) was carried out to imbalance the baseline characteristics.
Results: The optimal cut-off point for SII was defined as 640. SII was related to cancer types, but not to sex, age, tumor stage, smoking status and chemotherapy. Results showed that SII and NLR were significantly associated with OS in NSCLC patients in the univariate survival analysis, while PLR was not (HR=1.910, 95%CI 1.580 – 2.30, P = 0.000; HR=1.715, 95%CI 1.346 – 2.185, P = 0.000; HR=1.079, 95%CI 0.873 – 1.333, P = 0.482, respectively). Additionally, multivariate analysis revealed SII was an independent predictor of OS (H =1.933, 95%CI=1.598-2.338; P = 0.000). In the PSM analysis, SII still remained an independent predictor for OS (HR=1.942, 95%CI 1.591 – 2.371, P = 0.000). The prognostic impact of SII is superior to PLR and NLR.
Conclusions: SII was an independent prognostic predictor for advanced Non-small cell lung cancer patients.
Author Block: L. Dan, Y. Xia, Y. He, L. Weimin; West China Hospital, Sichuan University, Chengdu, China.
Background: Previous studies reported that systemic immune-inflammation index (SII) was associated with clinical outcome of several tumors. However, data related to lung cancer was rare. This study aims to clarify the clinical significance of SII in patients with advanced non-small cell lung cancer (NSCLC).
Methods: A total of 523 patients with staged III/IV NSCLC were enrolled in this retrospective study. SII was calculated with the formula SII = (platelet ×neutrophil)/ lymphocyte. The association among SII and clinical characteristics and overall survival (OS) of NSCLC was assessed. Propensity score matching (PSM) was carried out to imbalance the baseline characteristics.
Results: The optimal cut-off point for SII was defined as 640. SII was related to cancer types, but not to sex, age, tumor stage, smoking status and chemotherapy. Results showed that SII and NLR were significantly associated with OS in NSCLC patients in the univariate survival analysis, while PLR was not (HR=1.910, 95%CI 1.580 – 2.30, P = 0.000; HR=1.715, 95%CI 1.346 – 2.185, P = 0.000; HR=1.079, 95%CI 0.873 – 1.333, P = 0.482, respectively). Additionally, multivariate analysis revealed SII was an independent predictor of OS (H =1.933, 95%CI=1.598-2.338; P = 0.000). In the PSM analysis, SII still remained an independent predictor for OS (HR=1.942, 95%CI 1.591 – 2.371, P = 0.000). The prognostic impact of SII is superior to PLR and NLR.
Conclusions: SII was an independent prognostic predictor for advanced Non-small cell lung cancer patients.
|
Home
|
Inbox
|
Search
|